










































Did dendritic cell activation, induced by adenovirus-antibody
complexes, play a role in the death of Jesse Gelsinger?
Citation for published version:
Baker, A & Herzog, R 2020, 'Did dendritic cell activation, induced by adenovirus-antibody complexes, play a
role in the death of Jesse Gelsinger?', Molecular Therapy. https://doi.org/10.1016/j.ymthe.2020.02.010
Digital Object Identifier (DOI):
10.1016/j.ymthe.2020.02.010
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
www.moleculartherapy.org
CommentaryDid Dendritic Cell Activation,
Induced by Adenovirus-Antibody
Complexes, Play a Role in the
Death of Jesse Gelsinger?
Andrew H. Baker1 and Roland W. Herzog2
https://doi.org/10.1016/j.ymthe.2020.02.0101University of Edinburgh/BHF Centre for
Cardiovascular Science, Queen’s Medical Research
Institute, 47 Little France Crescent, Edinburgh
EH16 4TJ, UK; 2Herman B. Wells Center for
Pediatric Research, Indiana University School of
Medicine, Indianapolis, IN, USA
Correspondence: Andrew H. Baker, Associate Editor
of Molecular Therapy, University of Edinburgh/BHF
Centre for Cardiovascular Science, Queen’s Medical
Research Institute, 47 Little France Crescent, Edin-
burgh EH16 4TJ, UK.
E-mail: andy.baker@ed.ac.ukWe are currently in an era of high hope for
the future of human gene therapy. Academic
breakthroughs, engagement by a broad range
of industries working through first-in-hu-
man studies with academics, expansive clin-
ical data, and clearer regulatory paths have
fueled the anticipation for success. In general
terms, the gene therapy pipeline is directly
linked to vector efficacy and the ability to
preferentially target a specific cell type or
tissue. However, for many diseases, this is
less straightforward because intravascular
delivery of the gene therapy agent may be
required. This comes with the caveat that in-
jection of vectors into the bloodstream ex-
poses the approach to a panacea of possible
interactions of the host with the vector that
might impact the therapeutic approach.
In 1999, a subject with ornithine transcarba-
mylase deficiency developed lethal sys-
temic inflammation following intra-arterial
administration of an adenovirus (Ad) vector.
Building on 20 years of improved knowledge
of innate immunity to gene therapy vectors, a
new study published in this issue of Molecu-
lar Therapy investigated a potential reason to
explain this event.
Ad-based vectors have been extensively used
for gene therapeutics and as genetic vaccines
via intradermal, intramuscular, or intratu-
moral injections.1 By contrast, their utility
for intravascular administration has been
much more challenging and controversial.
Ad vectors are characterized by their relative
ease of construction, modification of the
capsid, simplicity for clinical grade produc-
tion, and breadth of cell types that are trans-
duced upon exposure. On the other hand,
fundamental questions relating to the effect704 Molecular Therapy Vol. 28 No 3 March 20on a host either immunologically naive or
with anti-Ad immunity are still poorly under-
stood. With respect to vectors derived from
human type 5 (HAdV5), a transforming event
in the entire field of gene therapy was the
death of patient 019, later disclosed as Jesse
Gelsinger (see https://www.sciencehistory.
org/distillations/the-death-of-jesse-gelsinger-
20-years-later for a recent article). Mr. Gel-
singer was enrolled in a study for gene therapy
in the context of ornithine transcarbamylase
(OTC) deficiency.2 Eighteen hours after being
infused into the right hepatic artery with 6 
1011 particles/kg (>3  1013 total particles),
his clinical course wasmarked by systemic in-
flammatory response syndrome, dissemi-
nated intravascular coagulation, and multiple
organ system failure, leading to death 98 h
post-vector injection. Not only did this event
impact the entire field, but it underscored the
paucity in our understanding of host-vector
interactions, particularly in the context of a
host with memory immunity to HAdV5.
This fundamental lack of understanding in
host-HAdV5 interaction was also com-
pounded by the finding in the STEP vaccine
trial using HAdV5 for vaccination against
HIV, that subjects with pre-existing anti-
bodies to this virus actually showed increased
incidence of infection by HIV.3
While the reasons for Jesse Gelsinger’s death
are likely multiple and complex, 20 years
later we have a follow-up study that might
shed more light on what happened. In this
issue of Molecular Therapy, Somanathan
et al.4 revisit the hypothesis that a pre-exist-
ing anti-HAdV5 immune response was
responsible for a heightened host dendritic
cell (DC) activation, which may have been20 ª 2020 The American Society of Gene and Cea driving factor in the inflammatory
response. A series of findings in the study
are worth noting: the authors first showed
that both rabbit polyclonal antibodies to
HAdV5 or intravenous immunoglobulin
(IV-Ig) (a mixture of sera from human blood
donors) enhanced HAdV5-mediated gene
transfer into human DC cultures, a finding
consistent with several prior reports. Of
note, rabbits injected with HAdV5 vectors
produced type-specific antibodies directed
against the Ad hexon epitopes. This is critical
in these assays because at least two other
studies showed that anti-hexon antibodies
in IV-Ig are responsible for the activation
of DCs by HAdV5-IgG complexes. Addi-
tionally, the authors showed with the rabbit
antiserum that this also led to marked DC
activation, measured by CD80 expression
and interleukin-6 (IL-6) secretion. Similar
findings were observed in mouse bone
marrow-derived DCs, although one should
caution that HAdV5 can directly activate
mouse DCs. Further, when they assessed
the sera of three patients that had received
HAdV5-based topical gene therapy, they
showed that the two subjects that had
neutralizing antibodies (NAbs) to HAdV5
post-gene therapy also showed enhanced
HAdV5-mediated gene transfer in human
DCs and concomitant DC activation (similar
to observations by others). Moreover, when
they assessed 46 sera samples from random
human donors, they observed a broad range
of NAbs and, in some cases, enhanced DC
transduction, but DC activation in only 3
sera, a finding seemingly independent of
the level of HAdV5 NAb titers. These results
need to be interpreted carefully because, if
the NAb titer is high in anti-hexon NAbs,
immunoglobulin-complexed (IC)-HAdV5
will cause the majority of cells to undergoll Therapy.
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Commentarypyroptosis (see below). Then, there are few
cells remaining tomature and thematuration
effect is hidden (for example, see the undi-
luted serum in Figure 1C of Eichholz et al.5).
Furthermore, Perreau et al.6 also showed the
importance of FcgR I, -II, and -III in such a
process of human DC activation.
To mimic an in vivo environment, Somana-
than et al.4 passively infused IV-Ig into
mice prior to intravascular HAdV5 adminis-
tration and demonstrated an increase in
circulating pro-inflammatory cytokine IL-6
with kinetics similar to the Gelsinger case.
IL-6 levels in these mice injected with
HAdV5 alone were, however, 10-fold lower
than what others had reported.7 Finally,
they went back to a sample stored from Gel-
singer to ask whether the DC hypothesis was
possible. Worthy of noting, that this was a
frozen whole blood sample taken prior to
vector injection, so they used similar whole
blood samples to ensure correct controls.
Limitations in the quality, quantity, and pu-
rity of donor DCsmay cause assay variability,
but the salient findings are that the blood
sample from Gelsinger increased DC trans-
duction and activation, whereas the 6 other
samples, in general, all showed an enhanced
HAdV5 transduction, but limited enhance-
ment of costimulation and IL-6. The authors
therefore proposed that those who harbor an
equivalent anti-HAdV5 NAb titer constitute
approximately 5%–10% of potential subjects.
Alternatively, Jesse Gelsinger may have had a
unique distribution of HAdV5NAbs that can
target fiber, penton, base, and/or hexon.
As one might expect, conclusions about a
substantial event in the field should be
treated with caution. As already mentioned,
the mechanism by which Ig-complexed
HAdV5 induces the maturation and death
of human DCs has been described in detail
and showed that human DCs undergo acti-
vation and pyroptosis via AIM2 (absent in
melanoma 2)-dependent activation of an
inflammasome.5 Tran et al.8 showed that
numerous pro-inflammatory cytokines,
including IL-6, are released following
IC-Ad challenge. Conventional DCs (as
modeled by monocyte-derived DCs) make
up 0.3% to 1% of leukocytes and therefore
are capable of having a significant impact.Trained immunity, the transient (weeks)
metabolic and epigenetic reprogramming of
myeloid cells in the bone marrow, may also
be a potential avenue to explore.9 In this sce-
nario, when the monocytes and macro-
phages are released into the circulation,
they are primed for a heightened immune
response. While we are unaware of the im-
mune status of Jesse Gelsinger, or OTC pa-
tients in general, anyone would have been
excited and anxious prior to a life event
such as the trial he enrolled in. This could,
in theory, have fostered a heightened im-
mune profile and possibly impacted the
ensuing cytokine storm. Other potential
compounding factors include the ability of
HAdV5 to agglutinate human red blood
cells. Unlike mice, but similar to rats, human
red blood cells have a low level of CAR on
their surface.10,11 It has been known for
decades that high doses of HAdV5 can be
rapidly lethal in some rat strains, while
similar levels do little to mice.12 This phe-
nomenon, and the broader differences in
species dependency in host-HAdV5 interac-
tions, was not fully understood until 10 years
after the OTC trial.
As pointed out in the paper, the authors are
limited to the single clinical case and single
remaining blood sample but do provide
more power in some of the in vitro experi-
ments and animal studies. Analysis of blood
samples from the other subjects could have
added power and confidence to the DC
transduction and activation hypothesis and
link to clinical data (particularly IL-6 levels).
Indeed, for a number of reasons, other as-
pects of the paper were with limited samples
and without power and, thereby, no robust
statistical assessments. Thus, definitive con-
clusions must be tempered with utmost
caution around robustness and sample sizes.
Further, causality in terms of the specific
antibody type, the lack of association with
NAb titer, and the importance of any find-
ings for other HAdV remain to be under-
stood in detail and require further valida-
tion—all important issues for the field.
Certainly, intravascular administration of
HAd-based vectors remains a logical approach
in many cases for gene therapeutics. Should
the findings highlighted herein be validatedMolecufurther and accepted by the community and
regulators, then one might imagine the ratio-
nale for screening subjects enrolled on
HAdV5-based trials for DC-mediated
enhancement in virus transduction and acti-
vation. This is likely clearly pertinent for
HAdV5-based vectors, but one cannot help
to reason that more research is needed to
understand the implications for other Ad
types, as many are prevalent in the human
population throughnatural infections. Finally,
Somanathan et al.4 speculate that the afore-
mentioned toxicity issues for HAdV5 gene
therapy might also be relevant for adeno-
associated virus (AAV), where some toxicity
has been noted at high vector doses. The situ-
ation and kinetics are very different, and one
would need to see specific studies on AAV to
imply such associations. However, the exis-
tence of a link between capsidmemory immu-
nity and high-dose intravascular administra-
tion for gene therapy is an important one,
and one that deserves further attention and
rigorous validation. With this new study, a
possible link has been suggested for the death
of Jesse Gelsinger, an event that is more than
simply a lasting memory for the field, but
also a case for the importance of immune
memory at high dose intravascular HAdV5
gene therapy.
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of Aquaporin 1: An Alternative
to Glaucoma Eye Drop Therapy?
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E-mail: komaromy@msu.eduGlaucoma is a group of optic neuropathies
and a leading cause of irreversible blindness
worldwide, affecting more than 70 million
people, with a rising prevalence in aging
populations.1,2 The hallmark and final com-
mon pathway of all forms of glaucoma is pro-
gressive retinal ganglion cell (RGC) death and
optic nerve degeneration.3 The pathogenic
triggering mechanisms are largely unknown,
but key risk factors include intraocular pres-
sure (IOP)-related biomechanical stress.3
Both medical and surgical therapies are avail-
able to control IOP, either by reducing pro-
duction or increasing drainage of aqueous
humor. While these treatments are quite
effective, there are shortfalls that may result
in persistent progressive vision loss despite
therapy.3,4 In this issue ofMolecular Therapy,
Wu et al.5 describe a new treatment strategy
that could result in effective, long-term con-trol of IOP. They propose to disrupt aqua-
porin 1 (AQP1) expression within the ciliary
epithelium by adeno-associated virus (AAV)-
mediated delivery of a CRISPR-Cas9 system
(Figure 1), and they provide proof-of-concept
in experimental mouse glaucoma models and
cultured human ciliary body.
In healthy eyes, IOP is maintained in a phys-
iologic range by the balance of aqueous
humor production by the ciliary body and
drainage through the iridocorneal angle (Fig-
ure 1). Most patients suffer from hypertensive
glaucoma with elevated IOP due to increased
aqueous humor outflow resistance.3 In the
most common disease forms, such as primary
open-angle glaucoma (POAG), the underly-
ing pathogenesis is still largely unknown and
a cure is not available.4 Current treatments
are limited to lowering IOP in order to slowor prevent further RGC loss and damage to
the optic nerve.3,4 Reduction of IOP is the
only proven method to treat glaucoma and
slow progression of vision loss; this can be
achieved by medical and surgical treatments,
including daily eye drops as well as laser and
incisional surgeries.3,4 Low patient adherence
rates for long-term self-administration of
IOP-lowering eye drops is a major problem
that contributes to disease progression despite
therapy.6,7
Strategies are being developed to address this
problem, most importantly by use of sus-
tained drug delivery technologies, with a
number of drug implants in pre-clinical and
clinical testing.6 By taking advantage of the
latest gene therapy vector and gene editing
advances, Wu et al.5 propose another alterna-
tive to eye drops by AAV-mediated intraoc-
ular delivery of CRISPR-Cas9 to disrupt the
AQP1 gene within the non-pigmented ciliary
epithelium, which encodes for a membranell Therapy.
